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ABSTRACT 
 
Molecular MRI (mMRI) is a special implementation of Molecular Imaging for the non invasive visualisation of 
biological  processes  at  the  cellular  and  molecular  level.  More  specifically,  mMRI  comprises  the  contrast  agent 
mediated alteration of tissue relaxation times for the detection and localisation of molecular disease markers (such as 
cell surface receptors, enzymes or signaling molecules), cells (e.g. lymphocytes, stem cells) or therapeutic drugs (e.g. 
liposomes, viral particles). MRI yields topographical, anatomical maps; functional MRI (fMRI) provides rendering of 
physiologic functions and magnetic resonance spectroscopy (MRS) reveals the distribution patterns of some specific 
metabolites. mMRI provides an additional level of information at the molecular or cellular level, thus extending MRI 
further beyond the anatomical and physiological level. These advances brought by mMRI are mandatory for MRI to be 
competitive in the age of molecular medicine. mMRI is already today increasingly used for research purposes, e.g. to 
facilitate the examination of cell migration, angiogenesis, apoptosis or gene expression in living organisms. In medical 
diagnostics, mMRI will pave the way toward a significant improvement in early detection of disease, therapy planning 
or monitoring of outcome and will therefore bring significant improvement in the medical treatment for patients.  
In general, Molecular Imaging demands high sensitivity equipment, capable of quantitative measurements to detect 
probes that interact with targets at the pico  or nanomolar level. The challenge to detect such sparse targets can be 
exemplified with cell surface receptors, a common target for molecular imaging. At high expression levels (bigger than 
106 per cell) the receptor concentration is approx. 10
15 per ml, i.e. the concentration is in the micromole range. Many 
targets, however, are expressed in even considerably lower concentrations. Therefore the most sensitive modalities, 
namely nuclear imaging (PET and SPECT) have always been at the forefront of Molecular Imaging, and many nuclear 
probes in clinical use today are already designed to detect molecular mechanisms (such as FDG, detecting high glucose 
metabolism). In recent years however, Molecular Imaging has commanded attention from beyond the field of nuclear 
medicine. Further imaging modalities to be considered for molecular imaging primarily include optical imaging, MRI 
and ultrasound. © 2006 Biomedical Imaging and Intervention Journal. All rights reserved. 
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CONTRAST AGENTS FOR mMRI
         
 
Clinical MRI scanners offer a spatial resolution of 
250  m in plane (small bore experimental systems allow 
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for  50   m  isotropic voxels  for  in  vivo  measurements), 
unlimited  depth  penetration  along  with  exceptionally 
good  soft  tissue  contrast.  The  above mentioned 
concentration  of  molecular  imaging  targets  in  the 
micromolar  range  is  challenging  and  requires 
sophisticated imaging strategies. Improvements in MRI 
design to reduce the lower detection limit are possible 
only to a certain extent; hence biophysical amplification  A. Hengerer et al. Biomed Imaging Interv J 2006; 2(2):e8  2 
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Figure 1 Principle of reporter genes for gene expression. The reporter gene (red) is co expressed with the gene of 
interest (green), often by using the same promoter for both genes. The reporter gene can be the HSV thymidine 
kinase  (phosphorylating  radioactive labeled  nucleoside analog,  which  get  trapped  in  the  cell  (A),  a  fluorescent 
protein like GFP (B), an intracellular target for a marker (C) or a cell membrane receptor as the transferin receptor 
(D). 
 
 
 
mechanisms  to  enhance  the  signal  from  the  label  are 
necessary.  
For  MRI,  two  different  classes  of  contrast  agents 
exist:  agents  that  influence  mainly  the  signal  in  T2  
(negative contrast agents, reducing the signal) or in T1 
weighted images (positive contrast agents, increasing the 
signal).  For  both  classes,  methods  for  signal 
amplification have been developed. In general, both take 
advantage  of  either  very  high  relaxivity  probes, 
background reduction (SNR optimisation) via activation 
of  low relaxivity  probes  by  the  targeted  molecular 
marker  (induced  changes  in  relaxivity)  or  pronounced 
tissue  accumulation.  The  latter  is  possible  only  with  a 
very  restricted  number  of  highly  expressed  molecular 
marker (e.g. fibrin for thrombosis imaging). 
 
Negative Contrast Agents 
For  T2 contrast  agents,  the  most  prominent  labels 
are  iron oxide  nanoparticles  (Superparamagnetic  Iron 
Oxide  (SPIO),  Very  Small  Paramagnetic  Iron  Oxide 
(VSPIO)  or  Ultrasmall  Superparamagnetic  Iron  Oxide 
(USPIO)). These particles usually consist of a crystalline 
iron oxide  core,  surrounded  by  polymer  coating,  often 
dextran, polyethyleneglycol or citrate. The advantage of 
these preparations is that each particle contains thousands 
of iron atoms resulting in very high T2 relaxivities of up 
to 200 (mMs)
 1 [1], which makes detection of even low 
concentrations of contrast agents ( mol to nmol range) 
possible. Noteworthy, particles smaller than 300 nm also 
produce a substantial T1 relaxation. 
Specific  population  of  cells  can  be  labeled  with 
magnetic  nanoparticles  and  followed  in  vivo  (cell 
tracking). Using this method, the spatial distribution of 
immuno competent cells into tumours over time can be 
studied as well as the movement of stem cells, neuronal 
cells or blood stem cells in vivo [2]. A widely excepted 
protocol  for  cell  labelling  using  SPIO  and  Polyamines 
has been published by Frank et al [3]. Key concerns with 
cell tracking are viability, differentiability, chromosomal 
stability of the labelled cells as well as the stability of 
label affiliation with the cell. 
Similar to PET imaging, MRI can be used to image 
gene  expression  and  to  assess  the  efficiency  of  gene 
delivery. Viral or non viral gene therapy schemes require 
targeting of the gene therapy vector to the tissue or cells 
of  interest.  Delivery  of  a  therapeutic  gene  can  be 
monitored  by  imaging  of  a  reporter  gene,  which  is 
introduced  into  the  gene  therapy  vector  and  expressed 
together  with  the  therapeutic  gene  (Figure  1).  The 
reporter gene can be encoded for the transferrin receptor 
(accumulating  iron  within  the  cell)  or  for  tyrosinase 
(catalysing the synthesis of melanin) [4]. Melanin has a 
high iron binding capacity, which results in a high signal 
intensity  of  the  henceforth  melanin  containing  cells  in 
T1 weighted  images  [5].  Compartmentalisation  of  iron 
oxide  particles  within  targeted  cells  can  produce 
significant signal amplification as well. Taking advantage 
of cell uptake processes via endocytosis or phagocytosis 
clearly  exceeds  the  concentration  that  can  be  achieved 
using cell surface receptor targeting alone. 
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Figure 2 Principle of the magnetic relaxation switch (see text). 
 
 
                                           (a)                                                                                                      (b) 
 
Figure 3 Plaque Imaging with Gadofluorine M (100  mol/kg bw), 24 h p.i. imaged with Siemens, 1.5 T, IR turbo flash (300/4/150/20°); (a) 
WHHL rabbit (with plaques), (b) New Zealand White (without plaques). Asterisk (*) indicates aorta (courtesy of B. Misselwitz, Schering 
AG, Berlin, Germany). 
 
 
 
A  method  named  “magnetic  relaxation  switch” 
facilitates the reversible activation of MR probes (Figure 
2). Target mediated aggregation of iron oxide particles to 
clusters produces a significant change in the relaxivity, 
which  can  be  utilised  to  image  enzyme  activities 
(telomerase,  endonucleases,  various  proteinases)  [6]. 
This  cluster formation  leads  to  an  amplification  of  the 
signal.  Based  on  “magnetic  relaxation  switches”,  MRI 
can  also  be  used  as  an  in  vitro  method  for  high 
throughput evaluation of biological specimens. 
 
Positive Contrast Agents 
Typical  T1 contrast  agents  are  small  molecular 
weight  compounds  containing  a  single  Lanthanide 
chelate as contrast producing element (e.g. Gadolinium 
DTPA). The tissue concentration necessary to image with 
these  T1 contrast  agents  on  a  molecular  level  is 
considerably  higher  than  the  required  concentration  of 
iron oxide particles, it has to be in the order of mMols, 
since T1 relaxivity values are usually only in the in the 5 
80  (mMs)
 1  range  [1].  Increasing  the  molecular  weight 
can  be  used  for  enhancing  the  relaxivity  by  restricting 
free rotation of the Gadolinium. This can be achieved by 
using polymeric backbones or in vivo binding of small 
sized contrast agents to serum proteins [7]. Multilabelled 
macromolecular  T1 contrast  agents  for  mMRI  take 
advantage of the fact that relaxivity is a linear function of 
the number of lanthanide ions per contrast agent (Figure 
3) [1]. Various labelling concepts, including Gadolinium 
loaded  liposomes  or  polymeres  with  thousands  of 
*  *  * 
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Gadolinium  atoms,  have  been  developed  to  overcome 
this limitation in sensitivity. For instance, the detection of 
angiogenetic  endothelium  was  achieved  by  large 
Gadolinium loaded liposomes, targeted to avb3 integrin 
receptors via peptides or antibodies [8]. Advantages on 
the  MRI  properties  may  be  counterbalanced  by 
drawbacks  in  pharmacokinetics  and  bio availability. 
High  molecular  weight  compounds  have  a  slower 
diffusion rate, which restricts delivery to certain tissues 
such as necrotic tumour centres or the CNS. 
Similar to T2 contrast agents, T1 contrast probes can 
be activated by different mechanisms, thus increasing the 
relaxivity of the agent. This target mediated increase of 
relaxivity leads to an increased contrast in the presence of 
the  target.  An  enzyme mediated  polymerisation  (e.g. 
bymyeloperoxidases up regulated in vulnerable plaques) 
of paramagnetic substrates into oligomers represents one 
possible  approach.  In  contrast  to  the  small  monomeric 
substrates  these  polymers  have  a  larger  hydrodynamic 
diameter and slower rotational rate of paramagnetic metal 
chelates. This results in a higher longitudinal relaxivity, 
and  since  the  oligomeres  are  eliminated  much  slower 
than the monomers all signal will come after a certain 
time only from the oligomere, retained at the side of the 
target's  presence  [9].  Another  method  utilises 
conformational changes in the chelates, allowing access 
of  bulk  water  to  the  inner  sphere  of  the  chelated 
lanthanide  upon  cleavage  of  a  protective  group  by  an 
enzyme or binding of calcium to the chelate. Monitoring 
of  gene  expression  with  T1  contrast  agents  can  be 
achieved  with  a  carbohydrate modified  Gadolinium 
chelate  to  image  the  activity  of  the  enzyme  ß 
galactosidase  as  marker  gene.  The  enzyme  cleaves  the 
carbohydrate  residue  from  the  chelate,  inducing  an 
increase in relaxivity by allowing access of water to the 
gadolinium [10]. 
Chemical exchange  saturation  transfer  (CEST) 
agents  are  another  emerging  class  of  negative  MRI 
contrast agents, which facilitate an activatable contrast. 
The  concept  of  CEST  can  be  utilised  to  obtain  highly 
amplified targeted agents. The principle is based on the 
fact that many molecules in the body exchange protons 
with bulk water through the selective RF irradiation of 
exchanging protons. After irradiating a millimolar pool 
of metabolite the energy is transferred to a nearby pool of 
water,  producing  a  strong  increase  in  enhancement  by 
means of chemical exchange. With CEST and its newer 
development  paraCEST  specific  metabolites  can  be 
detected.  Using  this  method,  the  concentration  of 
metabolites  such  as  glucose  can  be  evaluated  non 
invasively in vivo in all organs. It furthermore allows for 
the  measurement  of  the  pH  or  the  temperature. 
Multiparametric mMRI might become feasible as CEST 
agents  with  different  absorption  frequencies  of  the 
exchanging protons can be designed. The sensitivity of 
CEST can be improved further by incorporating larger 
number  of  exchangeable  protons  into  a  (polymeric) 
CEST agent. This has been accomplished by LIPOCEST 
agents, liposomes containing a paramagnetic shift reagent 
for water protons in their aqueous inner cavity [11]. 
Finally  an  “old  friend”  in  MRI  is  attracting 
increasing attention in the course of Molecular Imaging: 
Fluorine 19.  Xeno labels,  i.e.  elements  with  low 
physiological concentration in situ but appropriate gyro 
magnetic properties proved to provide superb traceability 
for mMRI.  
 
 
TRANSLATIONAL mMRI 
 
To date molecular imaging is increasingly used in 
laboratory studies. High resolution MRI is well suited to 
screen  mouse  models  for  tumours  and  other 
abnormalities  and  can  be  applied  to  non invasively 
follow up new experimental treatment strategies. While 
dedicated animal systems are available, clinical scanners 
are  also  very  capable  of  obtaining  high resolution 
images.  To  further  speed  up  translational  research,  a 
small animal MR scanner based on a clinical console has 
been introduced just recently (ClinScan, a joint Bruker 
and Siemens development). This system comes with an 
adapted  clinical  user  interface  and  supports  therefore 
most  of  the  features  and  sequences  used  on  clinical 
scanners.  Standardisation  of  the  system  ensures  easy 
protocol  transfer  from  and  to  clinical  scanners. 
Applications  being  developed  for  humans  on  clinical 
scanners  will  be  available  on  ClinScan.  On  the  other 
hand, any application being developed for animals can be 
easily  transferred  to  human  diagnostics.  In  addition, 
adaptations  for  clinical  scanner  are  underway  for 
experimental molecular imaging. These include, but are 
not  limited  to,  implementing  dedicated  small  animal 
protocols, (quantitative) analysis tools or dedicated small 
animal  RF  coils.  In  conclusion,  MRI  is  increasingly 
suited to carry molecular imaging from animal models 
into clinical practice.  
When  will  molecular  imaging  enter  clinical 
medicine?  Hot  (hyper intense)  spots,  which  add 
information on the molecular mechanisms underlying a 
disease  could  guide  radiologist  and  would  be  highly 
beneficial.  Hyper intense  hot  spots  can  be  caused  by 
highly  specific  accumulation  of  paramagnetic  contrast 
agents. Most macromolecular Gadolinium chelates are in 
an early pre clinical research stages and the time needed 
to  reach  clinical  applicability  is  considerable. 
Furthermore,  toxicity  concerns  due  to  the  prolonged 
retention of heavily Gadolinium loaded molecules within 
the  organism  must  be  disproved.  Superparamagnetic 
contrast agents can give easily detectable positive signal 
in  combination  with  imaging  techniques  such  as  off 
resonance imaging.  
Superparamagnetic iron oxide based contrast agents 
are  easily  detectable  on  T2 weighted  sequences,  even 
better so on T2* weighted images due to susceptibility 
effects. Iron oxide particles currently in clinical use can 
be utilised for cellular imaging of phagocyting cells, if 
combined  with  peptides,  helping  to  traverse  the 
membrane;  this  applicability  can  be  even  expanded  to 
any other cell type. Iron oxide particles can furthermore 
be functionalised with a wide variety of biological active  A. Hengerer et al. Biomed Imaging Interv J 2006; 2(2):e8  5 
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Figure  4  Mr PET  integrated 
solution.  PET  is  acquired  with  a 
ring  inserted  into  the  magnet  – 
simultaneous  acquisition  is 
possible.  
Figure 5 Molecular Imaging is one 
out  of  three  pillars  of  molecular 
medicine. A. Hengerer et al. Biomed Imaging Interv J 2006; 2(2):e8  6 
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molecules  such  as  targeting  moieties  of  peptides, 
antibody  (derivatives),  nucleic  acids  or  aptamers  to 
increase  specific  binding.  Therefore  a  wide  variety  of 
imaging agents for mMRI is emerging and can facilitate 
steps towards clinical mMRI. Translational research with 
iron oxide  particles  will  take  advantage  of  a  growing 
basis  of  installed  high  field  MRI  scanners,  since  the 
lower  detection  limit  decreases  with  increasing  field 
strength.  
 
 
DUAL MODALITY DEVICES FOR MOLECULAR IMAGING 
 
Besides being a powerful tool for the acquisition of 
molecular information, MRI is capable to add anatomical 
or functional information (fMRI, diffusion, perfusion) to 
molecular images acquired with other modalities such as 
PET,  SPECT  or  optical  imaging.  Combinations  of  CT 
and PET are increasingly used in clinical diagnostics. But 
there  are  some  unique  advantages  for  MR  PET. 
Isocentric and simultaneous measurements are possible, 
no  re positioning  of  the  patient,  MRI  can  provide 
navigator technique and may give attenuation correction 
for PET, there is a better soft tissue contrast, and lower 
radiation  exposure  enables  follow  up  studies.  The 
ongoing  development  in  imaging  software  and 
computing hardware facilitates co registration and image 
fusion of physically separated units without delay. But 
repositioning of the patient and time interval between the 
scans  makes  fusion  of  separately  obtained  images 
difficult  and  inherently  imprecise.  Integrated  devices 
would clearly be preferable even for economic reasons. 
Simon Cherry pioneered MR PET integration.  
Just recently the first fully integrated experimental 
set up (based on semiconductor detectors) for MR PET 
has  been  presented  by  Siemens  (Figure  4).  Academic 
sites  build  a  MR  optical  device.  Even  dual  probes  for 
optical and MR imaging have been developed [12] and 
triple modality probes are currently explored.  
 
 
THE BIG PICTURE 
 
Molecular  Imaging  is  one  out  of  three  pillars  of 
molecular  medicine,  i.e.  the  translation  of  basic 
molecular biology into medicine. The other two are in 
vitro diagnostics (IVD) and knowledge driven healthcare 
(Figure 5). To determine genetic predisposition, in vitro 
genomic or proteomic screening procedures will be used, 
such as DNA chip technologies or mass spectroscopy. IT 
tools  will  be  mandatory  as  complex  molecular 
information, be it in vivo or in vitro diagnostic, has to be 
integrated  by  IT  and  has  to  be  supplemented  by 
knowledge bases to leverage it into clinical applications. 
This  means  diagnostic  data  has  to  be  converted  into 
meaningful medical knowledge. 
The financial feasibility and medical practicability of 
molecular medicine including comprehensive diagnostics 
are debatable. The trial and error method will certainly 
continue  to  be  the  most  reasonable  approach  for  cost 
effective therapies without side effects. However, this is 
not the case with highly potential therapy regimes (i.e. 
therapies with a potential for serious side effects), cost 
intensive (molecular) treatment schemata (such as cell  or 
gene therapy) or therapies of chronic diseases. In such 
instances,  a  rational  therapy  selection  based  on 
comprehensive  diagnostic  data  is  a  decisive  factor  for 
efficient and cost sensitive patient care. One of the main 
cost drivers in medicine is inappropriate treatment over a 
prolonged  time.  From  a  medical  point  of  view,  many 
arising  molecular  therapy  concepts  are  based  on 
individualised drugs. These treatments must be tailored 
to the individual biochemical set up or disease stage of 
each  respective  patient  with  the  support  of  diagnostic 
data. Equipped with these patient specific data, a therapy 
regime  is  selected,  taking  into  account  the  different 
molecular  defects  for  each  disease  as  well  as  the 
particular clinical history and condition of a patient. 
An example of how mMRI could contribute to this 
scope is radiation treatment planning by semi automated 
lymph  nodal  cancer  staging  using  a  nanoparticle 
enhanced  lymphotropic  mMRI.  Preclinical  data  proves 
that  mMRI  demonstrate  great  promise  for  improving 
quality  of  diagnosis  in  general  for  oncologic   (tumour 
angiogenesis  imaging),  cardiovascular   (vulnerable 
plaque  imaging)  and  neurological  (Alzheimer’s  plaque 
imaging) diseases. 
 
 
APPENDIX 
 
 
 
A movie clip of a vesico vaginal fistula of a k ras induced tumour in the 
lung is available for download at: http://www.biij.org/2006/2/e8 
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